Friday, 16 October 2026European Markets

VRANKEN-POMMERY And LAURENT-PERRIER Have A High Dividend Yield And Return On Equity In The Beverages—Wineries & Distilleries Industry.

Loading stream...

(vianews) - vranken-pommery (vrap.pa) is among this list of stock assets with the highest dividend rate and return on equity on the beverages—wineries & distilleries industry.

financial asset price forward dividend yield return on equity
vranken-pommery (vrap.pa) €17.00 4.92% 2.66%
laurent-perrier (lpe.pa) €122.00 1.67% 11.21%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. vranken-pommery (vrap.pa)

4.92% forward dividend yield and 2.66% return on equity

vranken-pommery monopole société anonyme produces and sells wines and champagnes in europe, north america, and the asia pacific. it offers its products under the champagne charles lafitte, champagne demoiselle, champagne pommery, champagne heidsieck & c° monopole, champagne vranken – diamant, champagne germain, sao pedro, rozès, and grifo brands. vranken-pommery monopole société anonyme was founded in 1976 and is headquartered in reims, france.

earnings per share

as for profitability, vranken-pommery has a trailing twelve months eps of €1.15.

pe ratio

vranken-pommery has a trailing twelve months price to earnings ratio of 14.78. meaning, the purchaser of the share is investing €14.78 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.66%.

volume

today's last reported volume for vranken-pommery is 2274 which is 16.55% above its average volume of 1951.

moving average

vranken-pommery's worth is higher than its 50-day moving average of €16.98 and under its 200-day moving average of €17.65.

revenue growth

year-on-year quarterly revenue growth grew by 4.9%, now sitting on 339.97m for the twelve trailing months.

more news about vranken-pommery.

2. laurent-perrier (lpe.pa)

1.67% forward dividend yield and 11.21% return on equity

laurent-perrier s.a. produces and sells champagne wines. the company sells its products mainly under the laurent-perrier, salon, delamotte, and champagne de castellane brands. it also sells wines. laurent-perrier s.a. was founded in 1812 and is headquartered in tours-sur-marne, france.

earnings per share

as for profitability, laurent-perrier has a trailing twelve months eps of €9.93.

pe ratio

laurent-perrier has a trailing twelve months price to earnings ratio of 12.29. meaning, the purchaser of the share is investing €12.29 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.21%.

volatility

laurent-perrier's last week, last month's, and last quarter's current intraday variation average was a negative 0.64%, a negative 0.34%, and a positive 1.32%.

laurent-perrier's highest amplitude of average volatility was 1.47% (last week), 1.47% (last month), and 1.32% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, laurent-perrier's stock is considered to be overbought (>=80).

more news about laurent-perrier.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
VRANKEN-POMMERY And LAURENT-PERRIER Have A High Dividend Yield And Return On Equity In The Beverages—Wineries & Distilleries Industry. | ViaNews EU